{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:49:28Z","timestamp":1791038968780,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,18]],"date-time":"2001-12-18T00:00:00Z","timestamp":1008633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our study aimed to determine whether riluzole, which has shown efficacy as a disease\u2010modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective strategy with good tolerability. The efficacy of riluzole was evaluated in marmosets by testing its ability to reduce MPTP\u2010induced behavioral deficits and loss of dopaminergic nigral neurons. Marmosets were divided into two groups of four animals each: animals in Group 1 were injected twice with MPTP (2 mg\/kg subcutaneous) and treated with riluzole (10 mg\/kg per os b.i.d.), animals in Group 2 (controls) were injected with MPTP and with the vehicle of riluzole. A third group of marmosets which did not receive MPTP or riluzole drug was introduced for neurohistopathological studies (normal animals). Marmosets treated with riluzole preserved a better motor function and neurological performance through the 26 days of assessment when compared with the controls. Histologically, there was sparing of TH\u2010 and Nissl\u2010stained nigral neurons and of TH\u2010stained terminals in the striatum and the putamen in the group treated with riluzole compared to the controls. We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD. \u00a9 2001 Movement Disorder Society.<\/jats:p>","DOI":"10.1002\/mds.1272","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T18:17:27Z","timestamp":1030299447000},"page":"13-19","source":"Crossref","is-referenced-by-count":47,"title":["Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence"],"prefix":"10.1002","volume":"17","author":[{"given":"Maria C.","family":"Obinu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Reibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Moussaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Imperato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00478.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.12.2143"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540340109020"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601113340202"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00370302"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0026-895X(25)10187-9","article-title":"Block of the rat brain IIA sodium channel \u03b1 subunit by the neuroprotective drug riluzole","volume":"45","author":"Hebert T","year":"1994","journal-title":"Mol Pharmacol"},{"issue":"4","key":"e_1_2_5_8_2","first-page":"s223","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble A","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.1996.tb00289.x"},{"key":"e_1_2_5_10_2","first-page":"255","article-title":"Efficacy of riluzole in the treatment of amyotrophic lateral sclerosis","volume":"8","author":"Meininger V","year":"1997","journal-title":"Rev Contemp Pharmacother"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90597-Z"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90037-I"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(85)90196-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90147-A"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403033300901"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91680-3"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90108-J"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90804-Q"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199601310-00003"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)00144-3"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)12137-S"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390203"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)00247-5"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.62"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199412000-00063"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199410270-00042"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(96)00249-7"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00537-8"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1037\/0735-7044.107.6.1093","article-title":"Effects of amygdala, hippocampus, and periaqueductal gray lesions on short\u2010and long\u2010term contextual fear","volume":"107","author":"Kim JJ","year":"1993","journal-title":"Behav Neurosci"},{"key":"e_1_2_5_30_2","first-page":"121","article-title":"Mechanisms responsible for reduced contextual conditioning with massed unsignaled unconditional stimuli","volume":"19","author":"Fanselow MS","year":"1993","journal-title":"J Exp Physiol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199607)23:3<192::AID-SYN8>3.0.CO;2-3"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/29.4.6166661"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90349-K"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1994.1058"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-67491-4"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00362-O"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00188-4"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(88)90066-3"},{"key":"e_1_2_5_39_2","volume-title":"Neurodegenerative disorders: the role played by endotoxins and xenobiotics","author":"Hornykiewicz O","year":"1988"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92143-0"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(92)90270-U"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440726"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.1272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.1272","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.1272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:43:32Z","timestamp":1760964212000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.1272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1002\/mds.1272"],"URL":"https:\/\/doi.org\/10.1002\/mds.1272","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}